Na. Cataldo et al., Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone, FERT STERIL, 76(5), 2001, pp. 1057-1059
Objective: To determine the metabolic and reproductive effectiveness of ros
iglitazone in polycystic ovary syndrome (PCOS).
Design: Case report.
Setting: Academic clinical practice and General Clinical Research Center.
Patient(s): A 25-year-old woman with PCOS.
Intervention(s): Rosiglitazone maleate, 4 mg daily for 5 months until conce
ption.
Main Outcome Measure(s): Insulin sensitivity by steady-state plasma glucose
technique; serum androgens, progesterone, and hCG; and pelvic ultrasound i
mages.
Result(s): Rosiglitazone. treatment for 5 months improved insulin sensitivi
ty, lowered serum free testosterone, and resulted in spontaneous ovulation
and conception.
Conclusion(s): Rosiglitazone is a promising insulin sensitizer for treatmen
t of PCOS. Clinical trials are warranted. (C) 2001 by American Society for
Reproductive Medicine.